• Explore /
  • Poster
  • / Survival outcomes with CPX-351 vs 7+3 by baseline bone marrow blast percentage in older adults with newly diagnosed high-risk or secondary acute myeloid leukemia: A 5-year follow-up study.

Survival outcomes with CPX-351 vs 7+3 by baseline bone marrow blast percentage in older adults with newly diagnosed high-risk or secondary acute myeloid leukemia: A 5-year follow-up study.

Abstract Poster

Authors

Ellen Ritchie

Ellen K. Ritchie

Weill Cornell Medicine, The New York Presbyterian Hospital, New York, NY

Ellen K. Ritchie , Tara L. Lin , Laura F. Newell , Robert K. Stuart , Scott R. Solomon , Richard M. Stone , Gary J. Schiller , Matthew Joseph Wieduwilt , Eileen A. Ryan , Nalina Dronamraju , Jeffrey E. Lancet , Jorge E. Cortes

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

Track

Hematologic Malignancies

Sub Track

Acute Leukemia

Clinical Trial Registration Number

NCT01696084

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 7027)

DOI

10.1200/JCO.2023.41.16_suppl.7027

Abstract #

7027

Poster Bd #

157

Abstract Disclosures

Similar Posters

First Author: Jeffrey E. Lancet

First Author: Tara L. Lin

First Author: Jonathan E. Kolitz

First Author: Jeffrey E. Lancet